LEEM president asked to stay on until 2010

25 May 2008

The management board of the French drug industry association (LEEM) has asked Christian Lajoux to serve an additional two-year term as president of the group. A LEEM spokesperson told the Marketletter that the move was out of the ordinary and reflected Mr Lajoux's perceived strengths in pursuing a vigorous campaign against excessive taxes and regulations, which threaten the research-based drug industry's future in France (see page 11). The LEEM's annual general meeting on June 13 will consider the proposal.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight